On Dec 15, Exelixis, Inc. (NASDAQ:EXEL) announced its collaborator Genentech, a member of the Roche Group, has completed the filing of its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Exelixis, Inc. … Continue reading Market Wrap Up: Exelixis, Inc. (NASDAQ:EXEL), Sirius XM Holdings Inc. (NASDAQ:SIRI), Genocea Biosciences, Inc. (NASDAQ:GNCA), People’s United Financial (NASDAQ:PBCT), Atlantic Tele-Network (NASDAQ:ATNI)